



## (51) International Patent Classification:

A61P 11/00 (2006.01) C07D 487/10 (2006.01)  
A61K 31/4965 (2006.01) C07D 471/04 (2006.01)  
C07D 241/26 (2006.01) C07D 473/34 (2006.01)  
C07D 403/12 (2006.01) C07D 487/04 (2006.01)

## (21) International Application Number:

PCT/EP2008/067110

## (22) International Filing Date:

9 December 2008 (09.12.2008)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

07122739.1 10 December 2007 (10.12.2007) EP

## (71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): BHALAY, Gurdip [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). BUDD, Emma [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). BLOOMFIELD, Graham Charles [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). COLLINGWOOD, Stephen Paul [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). DUNSTAN, Andrew [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB).

(GB). EDWARDS, Lee [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). GEDECK, Peter [DE/CH]; Rue de l'Union 5, CH-1800 Vevey (CH). HOWSHAM, Catherine [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). HUNT, Peter [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). HUNT, Thomas Anthony [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). OAKLEY, Paul [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). SMITH, Nichola [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB).


(74) Agent: VÖGELI-LANGE, Regina; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

## (54) Title: ORGANIC COMPOUNDS



(I)

(57) Abstract: A compound of Formula (I) in free or salt or solvate form, where  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. Diseases named to respond to epithelial sodium channel (ENaC) blockade are inflammatory or allergic conditions selected from: cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**(88) Date of publication of the international search report:**

13 August 2009